The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia
Frontiers in Psychiatry · 04.10.2024 · 15
DOI: 10.3389/fpsyt.2024.1421554 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 04.10.2024. Verfasst von Samantha E Yohn und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb, Princeton, NJ, United States. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cognitive impairment is a core symptom of schizophrenia and a major determinant of poor long-term functional outcomes. Despite considerable efforts, we do not yet have any approved pharmacological treatments for cognitive impairment associated with schizophrenia (CIAS). A combination of advances in pre-clinical research and recent clinical trial findings have led to a resurgence of interest in the cognition-enhancing potential of novel muscarinic acetylcholine receptor (mAChR) agonists in schizophrenia. This article provides an overview of the scientific rationale for targeting M 1 and M 4 mAChRs. We describe the evolution of neuroscience research on these receptors since early drug discovery efforts focused on the mAChR agonist xanomeline. This work has revealed that M 1 and M 4 mAChRs are highly expressed in brain regions that are implicated in cognition. The functional significance of M 1 and M 4 mAChRs has been extensively characterized in animal models via use of selective receptor subtype compounds through neuronal and non-neuronal mechanisms. Recent clinical trials of a dual M 1 /M 4 mAChR agonist show promising, replicable evidence of potential pro-cognitive effects in schizophrenia, with several other mAChR agonists in clinical development.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Bristol Myers Squibb, Princeton, NJ, United States.
- Division of Psychology, University of Miami, Miami, FL, United States.
- Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, United States.
Zitieren
APA
Yohn, S. E., Harvey, P. D., Brannan, S. K., & Horan, W. P. (2024). The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1421554
Vancouver
Yohn SE, Harvey PD, Brannan SK, Horan WP. The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia. Frontiers in Psychiatry. 2024;15. doi:10.3389/fpsyt.2024.1421554
BibTeX
@article{Yohn2024,
author = {Yohn, Samantha E and Harvey, Phillip D and Brannan, Stephen K and Horan, William P},
title = {The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia},
journal = {Frontiers in Psychiatry},
year = {2024},
volume = {15},
doi = {10.3389/fpsyt.2024.1421554}
}
EUVIMED